9267.T
Genky DrugStores Co., Ltd. [9267.T] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
9267.T Stock Summary
Top 10 Correlated ETFs
9267.T
Top 10 Correlated Stocks
9267.T
In the News
9267.T Financial details
Company Rating
Strong Buy
Market Cap
96.46B
Income
5.58B
Revenue
177.15B
Book val./share
2870.19
Cash/share
267.59
Dividend
25
Dividend %
0.45%
Employees
1.75K
Optionable
No
Shortable
Yes
Earnings
22 Apr 2024
P/E
16.47
Forward P/E
-
PEG
6.29
P/S
0.49
P/B
2
P/C
22.46
P/FCF
-
Quick Ratio
0.23
Current Ratio
0.91
Debt / Equity
0.72
LT Debt / Equity
0.53
-
-
EPS (TTM)
367.45
EPS next Y
-
EPS next Q
-
EPS this Y
7.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.43%
Revenue last 5Y
10.23%
Revenue Q/Q
-3.79%
EPS Q/Q
13.78%
-
-
-
-
SMA20
-5.03%
SMA50
-4.2%
SMA100
22.05%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
13%
ROC
0.1%
Gross Margin
20%
Oper. Margin
4%
Profit Margin
3%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3920.0-6840.0
52W High
-12.13%
52W Low
+53.32%
RSI
39
Rel Volume
1
Avg Volume
36.97K
Volume
37K
Perf Week
-4.6%
Perf Month
-3.06%
Perf Quarter
18.07%
Perf Half Y
13.4%
-
-
-
-
Beta
0.187
-
-
Volatility
115.69%, 173.52%
Prev Close
-3.22%
Price
6010
Change
-1.31%
9267.T Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 6.73K | 8.14K | 9.38K | 10.19K | 11.13K | |
| Net income per share | 174.7 | 181.52 | 318.35 | 291.18 | 313.77 | |
| Operating cash flow per share | 278.5 | 488.3 | 795.62 | 400.29 | 577.82 | |
| Free cash flow per share | -415.95 | -236.84 | 205.62 | -291.93 | -76.07 | |
| Cash per share | -68.71 | 218.55 | 291.41 | 117.73 | 116.25 | |
| Book value per share | 1.64K | 1.82K | 2.12K | 2.39K | 2.68K | |
| Tangible book value per share | 1.62K | 1.8K | 2.09K | 2.36K | 2.66K | |
| Share holders equity per share | 1.64K | 1.82K | 2.12K | 2.39K | 2.68K | |
| Interest debt per share | 1.43K | 2.01K | 1.89K | 2.04K | 2.14K | |
| Market cap | 39.3B | 53.96B | 58.89B | 51B | 66.81B | |
| Enterprise value | 58.86B | 77.73B | 79.53B | 76.53B | 93.83B | |
| P/E ratio | 14.57 | 19.58 | 12.19 | 11.54 | 14.02 | |
| Price to sales ratio | 0.38 | 0.44 | 0.41 | 0.33 | 0.4 | |
| POCF ratio | 9.14 | 7.28 | 4.88 | 8.39 | 7.61 | |
| PFCF ratio | -6.12 | -15.01 | 18.87 | -11.51 | -57.84 | |
| P/B Ratio | 1.55 | 1.95 | 1.83 | 1.41 | 1.64 | |
| PTB ratio | 1.55 | 1.95 | 1.83 | 1.41 | 1.64 | |
| EV to sales | 0.57 | 0.63 | 0.56 | 0.49 | 0.56 | |
| Enterprise value over EBITDA | 7.67 | 9.27 | 7.42 | 7.14 | 7.75 | |
| EV to operating cash flow | 13.69 | 10.49 | 6.59 | 12.59 | 10.7 | |
| EV to free cash flow | -9.17 | -21.62 | 25.49 | -17.27 | -81.24 | |
| Earnings yield | 0.07 | 0.05 | 0.08 | 0.09 | 0.07 | |
| Free cash flow yield | -0.16 | -0.07 | 0.05 | -0.09 | -0.02 | |
| Debt to equity | 0.87 | 1.1 | 0.89 | 0.85 | 0.8 | |
| Debt to assets | 0.32 | 0.37 | 0.31 | 0.32 | 0.31 | |
| Net debt to EBITDA | 2.55 | 2.83 | 1.93 | 2.38 | 2.23 | |
| Current ratio | 0.88 | 1.01 | 0.93 | 0.84 | 0.86 | |
| Interest coverage | 81.92 | 70.34 | 113.39 | 96.04 | 95.84 | |
| Income quality | 1.11 | 1.84 | 1.81 | 1 | 1.31 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.14 | 0.14 | 0.08 | 0.09 | 0.08 | |
| Sales general and administrative to revenue | 0.2 | 0.18 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -2.49 | -1.49 | -0.74 | -1.73 | -1.13 | |
| Capex to revenue | -0.1 | -0.09 | -0.06 | -0.07 | -0.06 | |
| Capex to depreciation | -3.23 | -2.93 | -2.21 | -2.29 | -2 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.54K | 2.73K | 3.9K | 3.95K | 4.35K | |
| ROIC | 0.06 | 0.05 | 0.08 | 0.06 | 0.07 | |
| Return on tangible assets | 0.04 | 0.03 | 0.05 | 0.05 | 0.05 | |
| Graham Net | -2.17K | -2.65K | -2.71K | -2.97K | -3.13K | |
| Working capital | -2.95B | 319.06M | -2.5B | -6.13B | -5.7B | |
| Tangible asset value | 25.02B | 27.38B | 31.77B | 35.86B | 40.32B | |
| Net current asset value | -20.8B | -26.18B | -26.49B | -29.37B | -30.82B | |
| Invested capital | 0.87 | 1.1 | 0.89 | 0.85 | 0.8 | |
| Average receivables | 3.57B | 3B | 4.09B | 4.62B | 5.5B | |
| Average payables | 13.33B | 15.52B | 18.44B | 20.09B | 21.38B | |
| Average inventory | 15.37B | 17.52B | 18.84B | 20.15B | 21.7B | |
| Days sales outstanding | 7.91 | 11.09 | 11.33 | 11.36 | 13.35 | |
| Days payables outstanding | 63.31 | 65.03 | 63.88 | 60.69 | 60.22 | |
| Days of inventory on hand | 76.95 | 68.89 | 63.14 | 61.71 | 61.03 | |
| Receivables turnover | 46.17 | 32.93 | 32.23 | 32.12 | 27.34 | |
| Payables turnover | 5.77 | 5.61 | 5.71 | 6.01 | 6.06 | |
| Inventory turnover | 4.74 | 5.3 | 5.78 | 5.91 | 5.98 | |
| ROE | 0.11 | 0.1 | 0.15 | 0.12 | 0.12 | |
| Capex per share | -694.45 | -725.14 | -590 | -692.23 | -653.89 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.72K | 2.66K | 2.95K | 3.09K | 2.97K | |
| Net income per share | 77 | 68.63 | 95.56 | 95.08 | 108.18 | |
| Operating cash flow per share | 159.92 | 162.14 | 172.95 | 170.94 | 179.49 | |
| Free cash flow per share | 159.92 | 162.14 | 172.95 | 170.94 | 179.49 | |
| Cash per share | 329.79 | 277.27 | 116.24 | 290.52 | 267.59 | |
| Book value per share | 2.52K | 2.58K | 2.68K | 2.76K | 2.87K | |
| Tangible book value per share | 2.5K | 2.56K | 2.66K | 2.73K | 2.87K | |
| Share holders equity per share | 2.52K | 2.58K | 2.68K | 2.76K | 2.87K | |
| Interest debt per share | 2.02K | 2.18K | 2.13K | 2.17K | 2.06K | |
| Market cap | 55.19B | 59.22B | 66.81B | 83.98B | 82.92B | |
| Enterprise value | 80.76B | 88.1B | 93.83B | 112.49B | 110.12B | |
| P/E ratio | 11.8 | 14.21 | 11.51 | 14.54 | 12.62 | |
| Price to sales ratio | 1.34 | 1.47 | 1.49 | 1.79 | 1.84 | |
| POCF ratio | 22.73 | 24.05 | 25.44 | 32.35 | 30.42 | |
| PFCF ratio | 22.73 | 24.05 | 25.44 | 32.35 | 30.42 | |
| P/B Ratio | 1.44 | 1.51 | 1.64 | 2 | 1.9 | |
| PTB ratio | 1.44 | 1.51 | 1.64 | 2 | 1.9 | |
| EV to sales | 1.96 | 2.18 | 2.09 | 2.4 | 2.44 | |
| Enterprise value over EBITDA | 42.57 | 58.85 | 45.55 | 53.49 | 45.22 | |
| EV to operating cash flow | 33.26 | 35.78 | 35.73 | 43.33 | 40.4 | |
| EV to free cash flow | 33.26 | 35.78 | 35.73 | 43.33 | 40.4 | |
| Earnings yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Free cash flow yield | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | |
| Debt to equity | 0.8 | 0.84 | 0.8 | 0.78 | 0.72 | |
| Debt to assets | 0.3 | 0.33 | 0.31 | 0.31 | 0.29 | |
| Net debt to EBITDA | 13.48 | 19.29 | 13.12 | 13.56 | 11.17 | |
| Current ratio | 0.86 | 0.86 | 0.86 | 0.91 | 0.92 | |
| Interest coverage | 71.2 | 154.89 | 67.28 | 134.33 | 84.71 | |
| Income quality | 2.08 | 2.36 | 1.81 | 1.8 | 1.66 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.09K | 2K | 2.4K | 2.43K | 2.64K | |
| ROIC | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Graham Net | -2.91K | -2.87K | -3.13K | -3.07K | -3.01K | |
| Working capital | -5.61B | -4.88B | -5.7B | -3.17B | -2.88B | |
| Tangible asset value | 37.97B | 38.84B | 40.32B | 41.52B | 43.17B | |
| Net current asset value | -29.39B | -29.91B | -30.82B | -31.92B | -29.95B | |
| Invested capital | 0.8 | 0.84 | 0.8 | 0.78 | 0.72 | |
| Average receivables | 2.83B | 2.92B | 4.56B | 5.11B | 4.01B | |
| Average payables | 20.47B | 19.62B | 20.35B | 22.21B | 22.48B | |
| Average inventory | 21.6B | 21.64B | 21.73B | 22.39B | 23.13B | |
| Days sales outstanding | 6.34 | 6.55 | 12.41 | 7.75 | 7.94 | |
| Days payables outstanding | 57.07 | 51.84 | 56.04 | 53.31 | 57.37 | |
| Days of inventory on hand | 61.37 | 58.78 | 56.79 | 53.47 | 60.5 | |
| Receivables turnover | 14.2 | 13.75 | 7.25 | 11.62 | 11.34 | |
| Payables turnover | 1.58 | 1.74 | 1.61 | 1.69 | 1.57 | |
| Inventory turnover | 1.47 | 1.53 | 1.58 | 1.68 | 1.49 | |
| ROE | 0.03 | 0.03 | 0.04 | 0.03 | 0.04 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
9267.T Frequently Asked Questions
What is Genky DrugStores Co., Ltd. stock symbol ?
Genky DrugStores Co., Ltd. is a JP stock and trading under the symbol 9267.T
What is Genky DrugStores Co., Ltd. stock quote today ?
Genky DrugStores Co., Ltd. stock price is $6010 today.
Is Genky DrugStores Co., Ltd. stock public?
Yes, Genky DrugStores Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 36.97K
- Market Capitalization 96.46B
- Employee 1.75K
- CEO Mr. Kenichi Fujinaga
- Headquarters Sakai,JP
- IPO Date 2010-02-22
-
Website
https://www.genkydrugstores.co.jp 
Genky DrugStores Co., Ltd. operates a chain of drug stores. The company was founded in 1988 and is headquartered in Sakai, Japan.
